Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: An iBFM-SG study

Blood

Volumn 111, Issue 3, 2008, Pages 1575-1583

  Forestier, Erik ^a   Izraeli, Shai ^b   Beverloo, Berna ^c   Haas, Oskar ^d   Pession, Andrea ^e   Michalová, Kyra ^f   Stark, Batia ^g   Harrison, Christine J ^h   Teigler Schlegel, Andrea ⁱ   Johansson, Bertil ^j  

^a UMEÅ UNIVERSITY   (Sweden)

^b TEL AVIV UNIVERSITY   (Israel)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ST ANNA CHILDREN S HOSPITAL   (Austria)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f CHARLES UNIVERSITY   (Czech Republic)

^g SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ Department of Human Genetics ^*  (Germany)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DOWN SYNDROME; HUMAN; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 38949098169     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-09-114231     Document Type: Article

References (69)

1. Krivit W, Good RA. Simultaneous occurrence of mongolism and leukemia: report of a nationwide survey. AMA J Dis Child. 1957;94:289-293.
2. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol. 2001;2:429-436.
3. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Pediatr Hematol Oncol. 1987;4:211-230.
4. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome: a report of 40 children of the AML-BFM Study Group. Leukemia. 1996;10:1677-1686.
5. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in inviduals with Down's syndrome. Lancet. 2000;355:165-169.
6. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. 2007. Available at http://cgap.nci.nih.gov/Chromosomes/ Mitelman. Accessed October 2007.
7. Izraeli S. Perspective: chromosomal aneuploidy in leukemia: lessons from down syndrome. Hematol Oncol. 2006;24:3-6.
8. Pui C-H, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11:1361-1367.
9. Watson MS, Carroll AJ, Shuster JJ, et al. Trisomy 21 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study (8602). Blood. 1993;82:3098-3102.
10. Litz CE, Davies S, Brunning RD, et al. Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia. 1995;9:1432-1439.
11. Dördelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Leukemia. 1998;12:645-651.
12. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321-325.
13. Bassal M, La MK, Whitlock JA, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005;44:21-28.
14. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106:4043-4049.
15. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128:797-804.
16. Secker-Walker LM, Hawkins JM, Prentice HG, Mackie PH, Heerema NA, Provisor AJ. Two Down syndrome patients with an acquired translocation, t(8;14)(q11;q32), in early B-lineage acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1993;70:148-150.
17. Lee ACW, Chan LC, Kwong KW. Down syndrome, acute lymphoblastic leukemia, and t(8;14)(q11;q32). Cancer Genet Cytogenet. 1996;88:92.
18. Forestier E, Johansson B, Borgström G, Kerndrup G, Johannsson J, Heim S. Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. Eur J Haematol. 2000;64:194-200.
19. Kaleem Z, Shuster JJ, Carroll AJ, et al. Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): a Pediatric Oncology Group study. Leukemia. 2000;14:238-240.
20. Byatt S-A, Cheung K-L, Lillington DM, et al. Three further cases of t(8;14)(q11.2;q32) in acute lymphoblastic leukemia. Leukemia. 2001;15:1304-1305.
21. Moore S, Suttle J, Bain S, Story C, Rice M. Acute lymphoblastic leukemia characterized by t(8;14)(q11.2;q32). Cancer Genet Cytogenet. 2003;141:1-4.
22. Lanza C, Volpe G, Basso G, et al. The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome. Leukemia. 1997;11:820-821.
23. Loncarevic IF, Roitzheim B, Ritterbach J, et al. Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion. Genes Chromosomes Cancer. 1999;24:272-277.
24. Uckun FM, Pallisgaard N, Hokland P, et al. Expression of TEL-AML1 fusion transcripts and response to induction therapy in standard risk acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:41-56.
25. Steiner M, Attarbaschi A, König M, et al. Equal frequency of TEL/AML1 rearrangements in children with acute lymphoblastic leukemia with and without Down syndrome. Pediatr Hematol Oncol. 2005;22:229-234.
26. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
27. Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer. 2005;5:11-20.
28. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986.
29. Alimena G, Billström R, Casalone R, Gallo E, Mitelman F, Pasquali F. Cytogenetic pattern in leukemic cells of patients with constitutional chromosome anomalies. Cancer Genet Cytogenet. 1985;16:207-218.
30. Carroll A, Civin C, Schneider N, et al. The t(1;22)(p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group study. Blood. 1991;78:748-752.
31. Lion T, Haas OA, Harbott J, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79:3325-3330.
32. Lu G, Altman AJ, Benn PA. Review of the cytogenetic changes in acute megakaryoblastic leukemia: one disease or several? Cancer Genet Cytogenet. 1993;67:81-89.
33. Martinez-Climent JA, Lane NJ, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995;9:95-101.
34. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood. 1998;91:608-615.
35. Bernstein J, Dastugue N, Haas OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216-218.
36. Trejo RMA, Aguilera RP, Nieto S, Kofman S. A t(1;22)(p13;q13) in four children with acute megakaryoblastic leukemia (M7), two with Down syndrome. Cancer Genet Cytogenet. 2000;120:160-162.
37. Dastugue N, Lafage-Pochitaloff M, Pagès M-P, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Français de Cytogéné tique Hématologique (GFCH). Blood. 2002;100:618-626.
38. Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol. 2003;121:566-577.
39. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol. 2005;132:576-583.
40. Kaneko Y, Rowley JD, Variakojis D, Chilcote RR, Moohr JW, Patel D. Chromosome abnormalities in Down's syndrome patients with acute leukemia. Blood. 1981;58:459-466.
41. Broomhead AF, Kwan YL, Zell NA, Lam-Po-Tang PRL, O'Gorman Hughes D. Acute leukemia characterized by trisomy 8 in Down's syndrome. Pathology. 1985;17:111-114.
42. Wang N, Leung J, Warrier RP, et al. Nonrandom chromosomal aberrations and clonal chromosomal evolution in acute leukemia associated with Down's syndrome. Cancer Genet Cytogenet. 1987;28:155-162.
43. Iselius L, Jacobs P, Morton N. Leukaemia and transient leukaemia in Down syndrome. Hum Genet. 1990;85:477-485.
44. Hayashi Y, Hanada R, Yamamoto K. Chromosome abnormalities and prognosis in childhood acute leukemia. Acta Paediatr Jpn. 1991;33:497-506.
45. Lampert F, Harbott J, Ritterbach J. Chromosomenaberrationen bei akuten Leukämien im Kindesalter: Analyse von 1009 Patienten. Klin Pädiatr. 1991;203:311-318.
46. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498. Blood. 1992;80:2210-2214.
47. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18:163-171.
48. ISCN. An International System for Human Cytogenetic Nomenclature. Mitelman F, ed. Basel, Switzerland: S. Karger;1995:1-114.
49. Forestier E, Andersen MK, Autio K, et al. Cytogenetic patterns in ETV6/RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia: a Nordic series of 245 cases and review of the literature. Genes Chromosomes Cancer. 2007;46:440-450.
50. Mertens F, Johansson B, Mitelman F. Dichotomy of hyperdiploid acute lymphoblastic leukemia on the basis of the distribution of gained chromosomes. Cancer Genet Cytogenet. 1996;92:8-10.
51. Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46:684-693.
52. Onodera N, McCabe NR, Rubin CM. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood. 1992;80:203-208.
53. Paulsson K, Panagopoulos I, Knuutila S, et al. Formation of trisomies and their parental origin in hyperdiploid childhood acute lymphoblastic leukemia. Blood. 2003;102:3010-3015.
54. Paulsson K, Mörse H, Fioretos T, Behrendtz M, Strömbeck B, Johansson B. Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2005;44:113-122.
55. Forestier E, Schmiegelow K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol. 2006;28:486-495.
56. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer. 2003;3:1-11.
57. Greaves MF. Aetiology of acute leukaemia. Lancet. 1997;349:344-349.
58. Kalwinsky DK, Raimondi SC, Bunin NJ, et al. Clinical and biological characteristics of acute lymphocytic leukemia in children with Down syndrome. Am J Med Genet. 1990;7:267-271.
59. Aguiar RCT, Sill H, Goldman JM, Cross NCP. The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster. Leukemia. 1997;11:233-238.
60. Mullighan CG, Goorha A, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758-764.
61. Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007;109:3451-3461.
62. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood. 1988;72:15-23.
63. Johansson B, Mertens F, Mitelman F. Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci. Genes Chromosomes Cancer. 1993;8:205-218.
64. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood. 1993;82:2157-2162.
65. Sinclair PB, Sorour A, Martineau M, et al. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Res. 2004;64:4089-4098.
66. Schaad K, Strömbeck B, Mandahl N, et al. FISH mapping of i(7q) in acute leukemias and myxoid liposarcoma reveals clustered breakpoints in 7p11.2: implications for formation and pathogenetic outcome of the idic(7)(p11.2). Cytogenet Genome Res. 2006;114:126-130.
67. Paulsson K, Johansson B. Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes. Pathol Biol. 2007;55:37-48.
68. Fong C, Brodeur GM. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet. 1987;28:55-76.
69. Brunning RD, Matutes E, Flandrin G, et al. Acute myeloid leukaemia not otherwise categorised. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours; pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001:91-105.